Industry News
Home /



Industry News

/Site-specific PEGylation of Human Growth Hormone by Mutated Sortase A
Site-specific PEGylation of Human Growth Hormone by Mutated Sortase A September 20,2023.
Published: 16 May 2018;   DOI:10.1007/s40242-018-8023-3
Chemical Research in Chinese Universities volume 34, pages428–433 (2018)

Site-specific PEGylation of Human Growth Hormone by Mutated Sortase A

Hui Shi, Qingyang Shi, James T. Oswald, Ying Gao, Leijiao Li & Yunhui Li


Human growth hormone(hGH), a classic therapeutic protein, which promotes growth and wound healing, is released from the pituitary gland.   As a protein drug, its short half-life is its main barrier to therapeutic efficacy.   Various strategies have been designed to prolong its serum half-life, the most common of which is the conjugation with polyethylene glycol(PEG), as this has been shown to significantly extend protein’s serum half-life.   However, PEGylation often results in random conjugation, which can lead to impaired protein function and hinder purification, characterization and evaluation of the PEGylated protein.   Therefore, site specific PEGylation is a promising direction for PEG-protein conjugation.   Here we took advantages of the mutated sortase A(7M) enzyme, which can enzymatically ligate the universal α-amino acids to a C-terminal tagged protein.   This then allows specific modification of the C-terminal of hGH with PEG.   This site-specific bound PEG-hGH has similar efficacy, receptor binding and cell proliferation as wild-type hGH;   however, pharmacokinetic analysis demonstrates that its serum half-life is almost 24 times that of wild-type hGH.   Herein, we provided a promising advancement in the development of site specific PEGylated therapeutic proteins.

Related products

Abbreviation: mPEG-NH2
Name: Methoxypoly(ethylene glycol) amine

For more product information, please contact us at:

US Tel: 1-844-782-5734
US Tel: 1-844-QUAL-PEG
CHN Tel: 400-918-9898

Copyright © XIAMEN SINOPEG BIOTECH CO., LTD. All Rights Reserved.